



INDEPENDENT AUDITOR'S REPORT

To The Members of Laurus Generics SA (Pty) Ltd

Report on the Standalone Ind AS Financial Statements

Opinion

We have audited the accompanying financial statements of Laurus Generics SA (Pty) Ltd ("the Company"), which comprise the Balance Sheet as at March 31, 2022, and the Statement of Profit and Loss (including Other Comprehensive Income), the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, and its profit, its cash flows and the changes in equity for the year ended on that date. These Audited Financial Statements is issued only for the limited purpose of incorporating in Consolidated Financial Statements and statutory filings.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibility for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.



Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and



other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Requirements

1. As required by Section 143(3) of the Act, based on our audit, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account.
 - d) In our opinion, the aforesaid financial statements comply with the Ind AS specified under Section 133 of the Act.

For Ramasamy Koteswara Rao and Co LLP
Chartered Accountants
Firm Registration Number :010396S/S200084




C V Koteswara Rao
Partner
Membership No.028353
UDIN : 22028353AHWMUD2823

Place : Hyderabad
Date: April 25, 2022

Laurus Generics SA (Pty) Ltd.

Balance Sheet as at March 31, 2022

Particulars	Notes	March 31,2022	March 31,2022	March 31,2021	March 31,2021
		Amount in ZAR	Amount in INR	Amount in ZAR	Amount in INR
Current Assets					
Financial Assets					
Trade Receivables	3	-	-	-	-
Cash and cash equivalents	4A	15,962,708	82,911,807	1,066	5,271
Other balances with banks	4B	41,229,557	214,150,192	-	-
Income tax assets (net)	7A	8,126,836	42,211,550	-	-
		<u>65,319,101</u>	<u>339,273,549</u>	<u>1,066</u>	<u>5,271</u>
Total Assets		<u><u>65,319,101</u></u>	<u><u>339,273,549</u></u>	<u><u>1,066</u></u>	<u><u>5,271</u></u>
EQUITY and LIABILITIES					
Shareholders' Funds					
Share Capital		2,000	9,886	2,000	9,886
Reserves and Surplus		46,215,072	231,866,339	(50,909)	(251,654)
Other Equity					
FCTNR		-	8,179,590	-	-
Total Equity		<u>46,217,072</u>	<u>240,055,816</u>	<u>(48,909)</u>	<u>(241,768)</u>
Current Liabilities					
Financial Liabilities					
Trade Payables	5	-	-	49,975	247,039
Other current liabilities	6	1,109,703	5,763,902	-	-
Income tax liabilities (net)	7B	17,992,326	93,453,832	-	-
		<u>19,102,029</u>	<u>99,217,733</u>	<u>49,975</u>	<u>247,039</u>
Total Equity and Liabilities		<u><u>65,319,101</u></u>	<u><u>339,273,549</u></u>	<u><u>1,066</u></u>	<u><u>5,271</u></u>
Summary of significant accounting policies	2.2				

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For Ramasamy Koteswara Rao and Co LLP

Chartered Accountants

Firm Registration Number :010396S/S200084

C V Koteswara Rao
Partner
Membership No.028353



For and on behalf of the Board of Directors
Laurus Generics SA (Pty) Ltd.


Dr. Satyanarayana C
Director


Babchand N
Director

Place: Hyderabad
Date: April 25, 2022

Place: Hyderabad
Date: April 25, 2022

Laurus Generics SA (Pty) Ltd.

Statement of Profit and Loss Account for the year ended March 31, 2022

Particulars	Notes	March 31,2022	March 31,2022	March 31,2021	March 31,2021
		Amount in ZAR	Amount in INR	Amount in ZAR	Amount in INR
INCOME					
I. Revenue from Operations	8	62,701,928	314,577,700	99,976	484,674
Other Income	9	368,022	1,846,379	-	-
Total Revenue (I)		63,069,950	316,424,080	99,976	484,674
EXPENSES					
II. Cost of Materials Consumed		-	-	-	-
Employee Benefits Expenses		-	-	-	-
Other Expenses	10	230,690	1,157,382	147,076	713,015
Total Expenses (II)		230,690	1,157,382	147,076	713,015
Earnings before Interest, Tax, Depreciation and Amortisation (EBITDA) (I-II)		62,839,260	315,266,698	(47,101)	(228,341)
III. Depreciation and Amortisation		-	-	-	-
Finance income	12	(1,423,091)	(7,139,695)	-	-
Finance costs	11	4,044	20,291	3,808	18,460
IV. Profit Before Tax for the year		64,258,306	322,386,102	(50,909)	(246,802)
V. Tax expense					
Current tax		17,992,326	90,268,109	-	-
Deferred tax		-	-	-	-
Income tax expense		17,992,326	90,268,109	-	-
VI. Profit for the year (IV-V)		46,265,981	232,117,994	(50,909)	(246,802)

Summary of significant accounting policies 2.2

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For Ramasamy Koteswara Rao and Co LLP

Chartered Accountants

For and on behalf of the Board of Directors

Laurus Generics SA (Pty) Ltd.

C V Koteswara Rao
Partner
Membership No.028353



Dr. Satyanarayana C

Dr. Satyanarayana C
Director

Babchand N

Babchand N
Director

Place: Hyderabad
Date: April 25, 2022

Place: Hyderabad
Date: April 25, 2022

Laurus Generics SA (Pty) Ltd.
Statement of Changes in Equity for the year ended March 31, 2022

a. Equity Share Capital

Equity Shares of ZAR 1.00 Each, Fully paid up	March 31, 2022		March 31, 2021	
	No.	ZAR	No.	Rs
As at March 31, 2021	2,000	2,000	2,000	9,886
Issued during the year	-	-	-	-
As at March 31, 2022	2,000	2,000	2,000	9,886

b. Other Equity

	Reserves and surplus	Items of Other Comprehensive Income	Total	Reserves and surplus	Items of Other Comprehensive Income	Total
	Retained Earnings	FCTNR		Retained Earnings	FCTNR	
	ZAR			INR		
At March 31, 2021	(50,909)	-	(50,909)	(251,654)	-	(251,654)
Profit for the year	46,265,981	-	46,265,981	232,117,994	8,179,590	240,297,584
Received during the year	-	-	-	-	-	-
At March 31, 2022	46,215,072	-	46,215,072	231,866,339	8,179,590	240,045,929

Laurus Generics SA (Pty) Ltd.
Cash Flow Statement for the year ended March 31, 2022

Particulars	March 31,2022	March 31,2022	March 31,2021	March 31,2021
	Amount in ZAR	Amount in INR	Amount in ZAR	Amount in INR
Profit before tax	64,258,306	322,386,102	(50,909)	(246,802)
Cash Flows from operating activities				
Adjustments for:				
Depreciation and amortisation	-	-	-	-
Interest expense	4,044	20,291	3,808	18,460
Operating profit before working capital changes	64,262,351	322,406,393	(47,101)	(228,341)
Foreign currency translation adjustments	-	8,184,862	-	(4,853)
Movement in working capital:				
Increase in trade receivables	-	-	-	-
Increase in trade payables	(49,975)	(247,039)	49,975	247,039
Increase in other current liabilities	1,109,703	8,949,625	-	-
Increase in other current assets	-	-	-	-
Cash generated from operations	65,322,079	339,293,840	2,874	13,845
Income tax paid	(8,126,836)	(42,211,550)	-	-
Net cash flows from operating activities (A)	57,195,243	297,082,290	2,874	13,845
Cash flows used in investing activities				
Purchase of property, plant and equipment, including intangible assets, capital work in progress and capital advances	-	-	-	-
Investment in deposits	(41,229,557)	(214,150,192)	-	-
Net cash flows used in investing activities (B)	(41,229,557)	(214,150,192)	-	-
Net cash flows from financing activities				
Proceeds from issue of equity shares	-	-	2,000	9,886
Interest paid	(4,044)	(20,291)	(3,808)	(18,460)
Net cash flows from/(used in) financing activities (C)	(4,044)	(20,291)	(1,808)	(8,574)
Net increase in cash and cash equivalents (A+B+C)	15,961,642	82,911,807	1,066	5,271
Cash and cash equivalents at the beginning of the year	1,066	-	-	-
Cash and cash equivalents at the year end	15,962,708	82,911,807	1,066	5,271
Components of cash and cash equivalents:				
Cash on hand	-	-	-	-
Balances with banks				
On current accounts	15,962,708	82,911,807	1,066	5,271
Total cash and cash equivalents	15,962,708	82,911,807	1,066	5,271

The accompanying notes are an integral part of the financial statements.

As per our report of even date


For Ramasamy Koteswara Rao and Co LLP
Chartered Accountants


C V Koteswara Rao
Partner
Membership No.028353



Place: Hyderabad
Date: April 25, 2022

For and on behalf of the Board of Directors
Laurus Generics SA (Pty) Ltd.


Dr. Salyanarayana C
Director


Babchand N
Director

Place: Hyderabad
Date: April 25, 2022

Laurus Generics SA (Pty) Ltd.

Notes to Financial Statements for the year ended March 31, 2022

Financial assets					
3.	Trade receivables	March 31,2022	March 31,2022	March 31,2021	March 31,2021
	Particulars	Amount in ZAR	Amount in INR	Amount in ZAR	Amount in INR
	Unsecured				
	Considered good	-	-	-	-
	Total	-	-	-	-
4.	Cash and cash equivalents and other bank balances				
	Particulars	Amount in ZAR	Amount in INR	Amount in ZAR	Amount in INR
	A) Cash and cash equivalents				
	Balances with banks				
	- On current accounts	15,962,708	82,911,807	1,066	5,271
	Total	15,962,708	82,911,807	1,066	5,271
	B) Other balances with banks				
	On deposit accounts				
	- Deposits with original maturity of less than three months	41,229,557	214,150,192		
	- Deposits with original maturity for more than 12 months	-	-		
	Total	41,229,557	214,150,192	-	-
	Less : Amount disclosed under other assets	-	-		
	Total	41,229,557	214,150,192	-	-
5.	Trade payables				
	Particulars	Amount in ZAR	Amount in INR	Amount in ZAR	Amount in INR
	Valued at amortised cost				
	- Total outstanding dues to creditors other than micro enterprises and small enterprises	-	-	49,975	247,039
	Total	-	-	49,975	247,039
	- Total outstanding dues to micro enterprises and small enterpr	-	-	-	-
	Total	-	-	-	-
6.	Other current liabilities				
	Particulars	Amount in ZAR	Amount in INR	Amount in ZAR	Amount in INR
	Current				
	Statutory dues	1,109,703	5,763,902	-	-
	Total	1,109,703	5,763,902	-	-
7.	Income tax assets/liabilities				
	Particulars	Amount in ZAR	Amount in INR	Amount in ZAR	Amount in INR
	A. Income tax assets				
	Advance tax	8,126,836	42,211,550		
	Total	8,126,836	42,211,550		
	B. Income tax liabilities				
	Provision for taxes (net)	17,992,326	93,453,832	-	-
	Total	17,992,326	93,453,832	-	-
8.	Revenue from operations				
	Particulars	Amount in ZAR	Amount in INR	Amount in ZAR	Amount in INR
	Other operating revenue	62,701,928	314,577,700	-	-
	Others	-	-	99,976	484,674
	Revenue from operations	62,701,928	314,577,700	99,976	484,674
9.	Other income				
	Particulars	Amount in ZAR	Amount in INR	Amount in ZAR	Amount in INR
	Tax Refund	366,434	1,838,410	-	-
	Net gain on foreign exchange fluctuations	1,588	7,969	-	-
	Total	368,022	1,846,379	-	-
10.	Other expenses				
	Particulars	Amount in ZAR	Amount in INR	Amount in ZAR	Amount in INR
	Consultancy and other professional charges	230,690	1,157,382	147,076	713,015
	Total	230,690	1,157,382	147,076	713,015
11.	Finance costs				
	Particulars	Amount in ZAR	Amount in INR	Amount in ZAR	Amount in INR
	Bank charges	4,044	20,291	3,808	18,460
	Total	4,044	20,291	3,808	18,460
12.	Finance Income				
	Particulars	Amount in ZAR	Amount in INR	Amount in ZAR	Amount in INR
	Interest income on				
	Margin money	1,423,091	7,139,695	-	-
	Total	1,423,091	7,139,695	-	-

Laurus Generics SA (Pty) Ltd.

Notes to financial statements for the year ended March 31, 2022

1. Corporate information

Laurus Generics SA (Pty) Ltd (LGSA), offers a broad range of Pharmaceutical and related services to the global Pharmaceutical community, situated in South Africa. LGSA, is a Pty Limited, incorporated under the laws of Republic of South Africa. LGSA is a wholly owned subsidiary of Laurus Labs Limited (Laurus). On June 15, 2020, the Laurus acquired 100 % shares of Phekolong Pharmaceuticals Pty Ltd, (renamed as Laurus Generics SA (Pty) Ltd) a wholly owned subsidiary of Pharmicare Limited t/a Aspen Pharmicare, South Africa.

2. Significant accounting policies

2.1 Basis of preparation

- (a) The financial statements of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS'), under the historical cost convention on the accrual basis except for certain financial instruments which are measured at fair values, the provisions of the Companies Act, 2013 ('the Act') (to the extent notified). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules issued there after.

2.2 Summary of significant accounting policies

(a) Use of Estimates

The preparation of financial statements in conformity with Indian Accounting Standards requires the Management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting year. Although these estimates are based on the Management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcome requiring a material adjustment to the carrying amounts of assets or liabilities in future years.

(b) Foreign currencies

The financial statements are presented in South African ZAR, which is the functional currency of the Company and the currency of the primary economic environment in which the Company operates. The financial statements are translated into Indian rupees for the purpose of preparing Group financial statements.

(c) Cash and cash equivalents

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Company's cash management.

(d) Measurement of EBITDA

The Company has elected to present earnings before interest, tax, depreciation and amortisation (EBITDA) as a separate line item on the face of the statement of profit and loss. The Company measures EBITDA on the basis of (profit) / loss from continuing operations and does not include depreciation and amortisation expense, finance costs and tax expense.

(f) foreign currency translation

The company converted the standalone Ind AS financial statements for presentation purposes from the relevant currency i.e ZAR for the business into the presentation currency (INR). The average foreign currency rate applied was 5.01703391 ZAR/INR for profit and loss account transactions. The closing foreign currency rate applied was 5.194094 ZAR/INR for Balance sheet items.

(g) Related Party Transactions

Names of related parties and description of relationship

	March 31, 2022		March 31, 2021	
	Amount in ZAR	Amount in INR	Amount in ZAR	Amount in INR
Holding Company				
a) Transactions During the Year				
i) Laurus Labs Limited				
Revenue		-		-
b) Closing Balances				
i) Laurus Labs Limited				
Disclosed Under Trade Payables		-		-

For Ramasamy Koteswara Rao and Co LLP

Chartered Accountants

Firm Registration Number :010396S/5200084

C V Koteswara Rao
Partner
Membership No.028353



For and on behalf of the Board of Directors

Laurus Generics SA (Pty) Ltd.

Dr. Satyanarayana C
Director

Babchand N
Director

Place: Hyderabad
Date: April 25, 2022

Place: Hyderabad
Date: April 25, 2022